AI English summary of an SEC filing — figures as filed
Zimmer Biomet ZBHZimmer Biomet said net sales for the 3 and 6 months ended June 30, 2025 increased 7.0% and 4.0%, respectively, compared to the same prior year periods. The Paragon 28 acquisition contributed 2.6% and 1.4%, respectively.
Key points
AI summaryZimmer Biomet said net sales for the 3 and 6 months ended June 30, 2025 increased 7.0% and 4.0%, respectively, compared to the same prior year periods. The Paragon 28 acquisition contributed 2.6% and 1.4%, respectively.
The company said net earnings decreased to $152.8 million for the 3 months and $334.9 million for the 6 months, compared to $242.8 million and $415.2 million in the same prior year periods. It cited as principal factors costs related to the Paragon 28 acquisition and increased interest expense from borrowings for the acquisition.
Zimmer Biomet said cash flows provided by operating activities for the 6 month period were $761.0 million, compared to $597.4 million in the same prior year period, and it paid $1,226.3 million, net of cash acquired, for the acquisition of Paragon 28. The company said proceeds from the issuance of senior notes were $1,748.1 million.
The company said full-year 2025 revenue is expected to grow year over year by approximately 6.7% to 7.7%, with Paragon 28 contributing 2.7%. It added that additional expenses related to tariffs are anticipated to be approximately $40 million for the full year, with a more significant impact in the second half of the year.
Key figures
Quarter ended June 30, 2025
- Revenue
- $2.1B
- Operating income
- $300M
- Net income
- $153M
- EPS
- $0.77
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Quarterly and Half-Year Net Sales Growth and Paragon 28 Contribution
Zimmer Biomet said net sales for the 3 and 6 months ended June 30, 2025 increased 7.0% and 4.0%, respectively, compared to the same prior year periods. The Paragon 28 acquisition contributed 2.6% and 1.4%, respectively.
Source · Based on the MD&A text of the filing
Net Earnings Decline and Factors Cited by the Company
The company said net earnings decreased to $152.8 million for the 3 months and $334.9 million for the 6 months, compared to $242.8 million and $415.2 million in the same prior year periods. It cited as principal factors costs related to the Paragon 28 acquisition and increased interest expense from borrowings for the acquisition.
Source · Based on the MD&A text of the filing
6-Month Cash Flows and Paragon 28 Acquisition Payment
Zimmer Biomet said cash flows provided by operating activities for the 6 month period were $761.0 million, compared to $597.4 million in the same prior year period, and it paid $1,226.3 million, net of cash acquired, for the acquisition of Paragon 28. The company said proceeds from the issuance of senior notes were $1,748.1 million.
Source · Based on the MD&A text of the filing
Full-Year Revenue Growth Outlook and Tariff Costs
The company said full-year 2025 revenue is expected to grow year over year by approximately 6.7% to 7.7%, with Paragon 28 contributing 2.7%. It added that additional expenses related to tariffs are anticipated to be approximately $40 million for the full year, with a more significant impact in the second half of the year.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…